No Data
The commercialization of the first year is about to begin, and the value turning point for Jian Shi Technology-B (9877.HK) has arrived.
As 2025 begins, the structural heart disease sector is reshaping the global cardiovascular industry at an astonishing speed. With Edwards Lifesciences' latest Earnings Reports revealing that TMTT Business revenue surged by 78% year-on-year, and Abbott Laboratories' structural heart disease sales exceeding 2.25 billion USD, the reports from leading companies confirm that this field is transitioning from the "technology validation phase" to the "scaling realization phase". Focusing domestically, under the dual logic of controlling costs in healthcare insurance and the domestic substitution 2.0, China's innovative forces are beginning to rewrite the global competitive landscape. A group of innovative medical instruments manufacturers, represented by Jienshi Technology, are opening up the interventional treatment for structural heart disease.
Jianshi Technology-B (09877.HK): KEN-VALVE has obtained NMPA registration approval and is actively promoting commercialization.
On March 25, Gelonghui reported that Jianshi Technology-B (09877.HK) announced that recently, one of its core products, the TAVR product Ken-Valve, has obtained registration approval from the National Medical Products Administration, as well as a medical instruments production license and national medical insurance coding. The company is actively promoting related commercialization work. Ken-Valve is a relatively rare TAVR product for treating aortic valve regurgitation (or combined with stenosis) on the market. The multi-specification design of the Ken-Valve and its advantage of large specifications are expected to cover a wide range of patient populations.
Express News | Jenscare Scientific - Ken-Valve Obtained Registration Approval From Nmpa China
Jenscare Scientific's 2024 Loss Narrows
Jianshi Technology-B (09877.HK) announced annual results with a significant reduction in losses to 0.186 billion yuan, accelerating the application process of core products on a Global scale.
On March 21, Glonghui announced that for the year ending December 31, 2024, the Other income and gains of JianShi Technology-B (09877.HK) reached 41.56 million yuan, with the annual loss significantly narrowing to 0.186 billion yuan, compared to a loss of 0.379 billion yuan in the same period last year. As of the date of this announcement, the company has several products at various stages of commercialization and research and development, covering multiple common structural heart disease treatment areas, including transcatheter tricuspid valve intervention, transcatheter aortic valve intervention, and transcatheter mitral valve intervention. The company's recent operational focus will be on the transcatheter tricuspid valve intervention placement.
Jianshi Technology-B (09877) released its annual performance, with R&D expenses of 0.143 billion yuan and is actively carrying out comprehensive commercialization activities.
Jianshi Technology-B (09877) released its annual performance report for the year ending December 31, 2024, the group achieved Other...
Pleasing Signs As A Number Of Insiders Buy Jenscare Scientific Stock
